FDA, Journey
Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. | The drug proved superiority in clearing lesions over ...
Alliance Global Partners analyst Scott Henry raised the firm’s price target on Journey Medical (DERM) to $11 from $8.50 and reiterated a Buy rating on the shares. The firm noted the “underwhelmed” ...
The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...
A digital health passport is an app, or online certification, that displays a traveller’s health or vaccination record. It can save lives, on both private and public levels.
SCOTTSDALE, Ariz., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling ...
Journey Medical (DERM) presented data assessing the dermal and systemic pharmacokinetics of oral DFD-29 versus oral Doxycycline 40 mg capsules in healthy subjects at the 44th Fall Clinical ...
Young car thieves are making life miserable and complicated for a Sanger family of six.The family spent hundreds of dollars ...
Medpage Today on MSN1d
Physician Explores Family's End-of-Life Journey in New PodcastMedPage Today spoke with Ungerleider about her experience as a physician and medical journalist reporting on her own family's ...
Journey Medical said on Monday the U.S. Food and Drug Administration has approved its drug for the treatment of a long-term ...
Recalling the experience, she told Society Plus, “I have been very cognisant of the stiff competition that comes with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback